Perspectives on reducing mortality attributed to acute myocardial infarction among patients with type 2 diabetes mellitus in multicenter randomized trials
https://doi.org/10.14341/DM200412-6
Abstract
A review of the scientific literature was conducted to investigate reducing mortality from acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). This included a review of literature comparing cardiovascular disease (CVD) treatment methods for AMI patients who have T2DM and those with normal carbohydrate metabolism. These treatments increase the life expectancy and greatly improve the quality of life of patients with acute myocardial infarction in both groups of patients. However, the risk of cardiovascular mortality in patients with T2DM compared with people with normal carbohydrate metabolism remains unchanged. The rapidly growing population of patients with T2DM will soon change our attitude towards the possibility of improving the prognosis and treatment of those with CVD.
About the Authors
Sergey V. Kakorin
Moscow City Clinical Hospital №4, Moscow
Russian Federation
MD, PhD, Head of emergency cardiology department
Competing Interests: No confict of interests declared.
Russian Federation
MD, PhD, Head of emergency cardiology department
Competing Interests: No confict of interests declared.
Ruben A. Iskandaryan
Pirogov Russian National Research Medical University, Moscow
Russian Federation
PhD in Biology
Competing Interests: No conflict of interests declared.
Russian Federation
PhD in Biology
Competing Interests: No conflict of interests declared.
Ashot M. Mkrtumyan
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow
Russian Federation
MD, PhD, Professor, Head of endocrinology and diabetology department
Competing Interests: No conflict of interests declared.
Russian Federation
MD, PhD, Professor, Head of endocrinology and diabetology department
Competing Interests: No conflict of interests declared.
References
1. Authors/Task Force M, Ryden L, Grant PJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035-3087. doi: 10.1093/eurheartj/eht108
2. Сегодня отмечается всемирный день борьбы против диабета [Электронный ресурс]: сервер Министерства здравоохранения Российской Федерации. – М., 2014. – Режим доступа: http://www.rosminzdrav.ru/news/2014/11/14/2111-segodnya-otmechaetsya-vsemirnyy-den-borby-protiv-diabeta. Дата обращения: 04.05.2015. [Today is World Diabetes Day [electronic resource]: the server of the Ministry of Health of the Russian Federation. Moscow; 2014. URL: http://www.rosminzdrav.ru/news/2014/11/14/2111-segodnya-otmechaetsya-vsemirnyy-den-borby-protiv-diabeta. Access date: 04.05.2015. (in Russ)]
3. Руяткина Л.А., Руяткин Д.С., Овсянникова А.К. Проблемы сахароснижающей терапии у пациентов с сахарным диабетом при остром коронарном синдроме. // Медицинский совет. – 2016. – №4 – С. 100-109. [Ruyatkina LA, Ruyatkina DS, Ovsyannikova AK. Problems of glucose-lowering therapy in patients with diabetes mellitus and acute coronary syndrome. Medical council. 2016;(4):100-109. (in Russ)].
4. Курочкина О.Н., Спасский А.А., Хохлов А.Л. Течение инфаркта миокарда с позиций гендерных различий: результаты ретроспективного исследования. // Проблемы женского здоровья. – 2012. – Т. 7. – №3 – С. 18-23. [Kurochkina ON, Spassky AA, Khokhlov AL Myocardial infarction within a position of gender differences: the results of a retrospective study. Problems of women’s health. 2012;7(3):18-23(in Russ)].
5. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. BJCP. 2001;48(5):643-648. doi: 10.1046/j.1365-2125.1999.00092.x
6. IDF diabetes atlas. Brussels: International Diabetes Federation; 2014.
7. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine. 2003;20(6):442-450. doi: 10.1046/j.1464-5491.2003.00972.x
8. Дедов И.И., Шестакова М.В., Александров А.А., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (6-й выпуск) // Сахарный диабет. – 2013. – Т. 16. – №1S – C. 1-120. [Dedov II, Shestakova MV, Aleksandrov AA, Galstyan GR, Grigoryan OR, Esayan RM, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;16(1S):1-120. (in Russ)]. doi: 10.14341/DM20131S1-121
9. de Vreede JJM, Gorgels APM, Verstraaten GMP, et al. Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol. 1991;18(3):698-706. doi: 10.1016/0735-1097(91)90792-8
10. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514-1523. doi: 10.1056/NEJMoa1310799
11. Tisminetzky M, Joffe S, McManus DD, et al. Decade-long trends in the characteristics, management and hospital outcomes of diabetic patients with ST-segment elevation myocardial infarction. Diab Vasc Dis Res. 2014;11(3):182-189. doi: 10.1177/1479164114524235
12. Lopez-de-Andres A, Jimenez-Garcia R, Hernandez-Barrera V, et al. National trends over one decade in hospitalization for acute myocardial infarction among Spanish adults with type 2 diabetes: cumulative incidence, outcomes and use of percutaneous coronary intervention. PLoS One. 2014;9(1):e85697. doi: 10.1371/journal.pone.0085697
13. Chung S-C, Gedeborg R, Nicholas O, et al. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. The Lancet. 2014;383(9925):1305-1312. doi: 10.1016/s0140-6736(13)62070-x
14. Kannel WB, McGee DL. Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study. Diabetes Care. 1979;2(2):120-126. doi: 10.2337/diacare.2.2.120
15. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234. doi: 10.1056/NEJM199807233390404
16. Mak K-H, Moliterno DJ, Granger CB, et al. Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France. J Am Coll Cardiol. 1997;30(1):171-179. doi: 10.1016/s0735-1097(97)00118-6
17. Chun BY, Dobson AJ, Heller RF. The Impact of Diabetes on Survival Among Patients With First Myocardial Infarction. Diabetes Care. 1997;20(5):704-708. doi: 10.2337/diacare.20.5.704
18. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102(9):1014-1019. doi: 10.1161/01.cir.102.9.1014
19. Lehto S, Pyörälä K, Miettinen H, et al. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med. 1994;236(3):291-297. doi: 10.1111/j.1365-2796.1994.tb00799.x
20. Rosengren A, Spetz CL, Koster M, et al. Sex differences in survival after myocardial infarction in Sweden; data from the Swedish National Acute Myocardial Infarction Register. Eur Heart J. 2001;22(4):314-322. doi: 10.1053/euhj.2000.2368
21. Melchior T, Gadsbøll N, Hildebrandt P, et al. Clinical Characteristics, Left and Right Ventricular Ejection Fraction, and Long-term Prognosis in Patients with Non-insulin-dependent Diabetes Surviving an Acute Myocardial Infarction. Diabet Med. 1996;13(5):450-456. doi: 10.1002/(SICI)1096-9136(199605)13:5<450::AID-DIA100>3.0.CO;2-6
22. Melchior T. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. Eur Heart J. 1999;20(13):973-978. doi: 10.1053/euhj.1999.1530
23. Fava S, Azzopardi J, Agius-Muscat H. Outcome of Unstable Angina in Patients with Diabetes Mellitus. Diabet Med. 1997;14(3):209-213. doi: 10.1002/(SICI)1096-9136(199703)14:3<209::AID-DIA324>3.0.CO;2-B
24. Löwel H, Koenig W, Engel S, et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Diabetologia. 2000;43(2):218-226. doi: 10.1007/s001250050032
25. Chyun D, Vaccarino V, Murillo J, et al. Cardiac Outcomes After Myocardial Infarction in Elderly Patients With Diabetes Mellitus. Am J Crit Care. 2002;11(6):504-519.
26. Savonitto S, Morici N, Cavallini C, et al. One-year mortality in elderly adults with non-ST-elevation acute coronary syndrome: effect of diabetic status and admission hyperglycemia. J Am Geriatr Soc. 2014;62(7):1297-1303. doi: 10.1111/jgs.12900
27. Butler MJ, Farrington C, Shaw JA, et al. The Impact of Diabetes Mellitus on Early and Late Mortality and Major Adverse Cardiac Events after Percutaneous Coronary Intervention with Drug-Eluting Stents. Heart, Lung and Circulation. 2007;16:S137. doi: 10.1016/j.hlc.2007.06.345
28. Falcão FJ, Alves CM, Barbosa AH, et al. Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction undergoing pharmacoinvasive treatment. Clinics. 2013;68(12):1516-1520. doi: 10.6061/clinics/2013(12)07
29. Chen PC, Chua SK, Hung HF, et al. Admission hyperglycemia predicts poorer short- and long-term outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Diabetes Investig. 2014;5(1):80-86. doi: 10.1111/jdi.12113
30. Rana JS, Mukamal KJ, Morgan JP, et al. Circadian Variation in the Onset of Myocardial Infarction: Effect of Duration of Diabetes. Diabetes. 2003;52(6):1464-1468. doi: 10.2337/diabetes.52.6.1464
31. Howangyin KY, Silvestre JS. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arterioscler Thromb Vasc Biol. 2014;34(6):1126-1135. doi: 10.1161/ATVBAHA.114.303090
32. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26(7):650-661. doi: 10.1093/eurheartj/ehi199
33. Kumbhani DJ, Healey NA, Thatte HS, et al. Patients with diabetes mellitus undergoing cardiac surgery are at greater risk for developing intraoperative myocardial acidosis. J Thorac Cardiovasc Surg. 2007;133(6):1566-1572. doi: 10.1016/j.jtcvs.2006.11.047
34. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. The Lancet. 2000;355(9206):773-778. doi: 10.1016/s0140-6736(99)08415-9
35. Fava S, Aquilina O, Azzopardi J, et al. The Prognostic Value of Blood Glucose in Diabetic Patients with Acute Myocardial Infarction. Diabet Med. 1996;13(1):80-83. doi: 10.1002/(SICI)1096-9136(199601)13:1<80::AID-DIA10>3.0.CO;2-W
36. Wahab NN, Cowden EA, Pearce NJ, et al. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002;40(10):1748-1754. doi: 10.1016/s0735-1097(02)02483-x
37. Suleiman M, Hammerman H, Boulos M, et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation. 2005;111(6):754-760. doi: 10.1161/01. CIR.0000155235.48601.2A
38. Blasco ML, Sanjuan R, Palacios L, et al. Prognostic value of admission glycated haemoglobin in unknown diabetic patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2014;3(4):347-353. doi: 10.1177/2048872614530574
39. Lazzeri C, Valente S, Chiostri M, et al. Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction. World J Cardiol. 2014;6(4):140-147. doi: 10.4330/wjc.v6.i4.140
40. Hoebers LP, Damman P, Claessen BE, et al. Predictive value of plasma glucose level on admission for short and long term mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol. 2012;109(1):53-59. doi: 10.1016/j.amjcard.2011.07.067
41. Trifunovic D, Stankovic S, Sobic-Saranovic D, et al. Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function. Cardiovasc Diabetol. 2014;13:73. doi: 10.1186/1475-2840-13-73
42. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25(21):1880-1890. doi: 10.1016/j.ehj.2004.07.027
43. Witte DR, Tesfaye S, Chaturvedi N, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48(1):164-171. doi: 10.1007/s00125-004-1617-y
44. Donnan PT, Boyle DIR, Broomhall J, et al. Prognosis following first acute myocardial infarction in Type 2 diabetes: a comparative population study. Diabet Med. 2002;19(6):448-455. doi: 10.1046/j.1464-5491.2002.00711.x
45. Gustafsson I, Hildebrandt P, Seibaek M, et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. Eur Heart J. 2000;21(23):1937-1943. doi: 10.1053/euhj.2000.2244
46. Barton DA, Dawood T, Lambert EA, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens. 2007;25(10):2117-2124. doi: 10.1097/HJH.0b013e32829baae7
47. Katon WJ, Lin EH, Russo J, et al. Cardiac risk factors in patients with diabetes mellitus and major depression. J Gen Intern Med. 2004;19(12):1192-1199. doi: 10.1111/j.1525-1497.2004.30405.x
48. Weitzman S, Wagner GS, Heiss G, et al. Myocardial Infarction Site and Mortality in Diabetes. Diabetes Care. 1982;5(1):31-35. doi: 10.2337/diacare.5.1.31
49. Stone PH, Raabe DS, Jaffe AS, et al. Prognostic significance of location and type of myocardial infarction: Independent adverse outcome associated with anterior location. J Am Coll Cardiol. 1988;11(3):453-463. doi: 10.1016/0735-1097(88)91517-3
50. Geltman EM, Ehsani AA, Campbell MK, et al. The influence of location and extent of myocardial infarction on long- term ventricular dysrhythmia and mortality. Circulation. 1979;60(4):805-814. doi: 10.1161/01.cir.60.4.805
51. Kelly PJ, Clarke PM, Hayes AJ, et al. Predicting mortality in people with type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data. Diabet Med. 2014;31(8):954-962. doi: 10.1111/dme.12468
52. Movahed MR. Diabetes as a risk factor for cardiac conduction defects: a review. Diabetes Obes Metab. 2007;9(3):276-281. doi: 10.1111/j.1463-1326.2006.00609.x
53. Kataoka M, Ito C, Sasaki H, et al. Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. Diabetes Res Clin Pract. 2004;64(1):51-58. doi: 10.1016/j.diabres.2003.10.009
54. Faglia E, Favales F, Calia P, et al. Cardiac Events in 735 Type 2 Diabetic Patients Who Underwent Screening for Unknown Asymptomatic Coronary Heart Disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care. 2002;25(11):2032-2036. doi: 10.2337/diacare.25.11.2032
55. Vrtovec B, Fister M, Poglajen G, et al. Diabetes does not affect ventricular repolarization and sudden cardiac death risk in patients with dilated cardiomyopathy. Pacing Clin Electrophysiol. 2009;32 Suppl 1:S146-150. doi: 10.1111/j.1540-8159.2008.02272.x
56. Kucharska-Newton AM, Couper DJ, Pankow JS, et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol. 2010;47 Suppl 1:161-168. doi: 10.1007/s00592-009-0157-9
57. Siscovick DS, Sotoodehnia N, Rea TD, et al. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord. 2010;11(1):53-59. doi: 10.1007/s11154-010-9133-5
58. Kamalesh M, Feigenbaum H, Sawada S. Challenge of identifying patients with diabetes mellitus who are at low risk for coronary events by use of cardiac stress imaging. Am Heart J. 2004;147(4):561-563. doi: 10.1016/j.ahj.2003.12.012
59. Go YY, Allen JC, Chia SY, et al. Predictors of mortality in acute heart failure: interaction between diabetes and impaired left ventricular ejection fraction. Eur J Heart Fail. 2014;16(11):1183-1189. doi: 10.1002/ejhf.119
60. Hjalmarson A, Gilpin EA, Nicod P, et al. Differing circadian patterns of symptom onset in subgroups of patients with acute myocardial infarction. Circulation. 1989;80(2):267-275. doi: 10.1161/01.cir.80.2.267
61. Кошельская О.А., Журавлева О.А., Карпов Р.С. Выбор комбинированной антигипертензивной терапии у пациентов с сахарным диабетом 2-го типа // Медицинский совет. – 2015. – №12 – С. 6-11. [Koshelskaya OA, Zhuravleva OA, Karpov RS. Selection of combinated antihypertensive therapy in patients with Type 2 diabetes mellitus. Medical council. 2015;(12):6-11. (In Russ)].
62. Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2014;7:169-183. doi: 10.2147/DMSO.S61438
63. Simmons RK, Sharp SJ, Sandbaek A, et al. Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial. Diabet Med. 2012;29(11):e409-416. doi: 10.1111/j.1464-5491.2012.03759.x
64. Hansen LJ, Siersma V, Beck-Nielsen H, de Fine Olivarius N. Structured personal care of type 2 diabetes: a 19 year follow-up of the study Diabetes Care in General Practice (DCGP). Diabetologia. 2013;56(6):1243-1253. doi: 10.1007/s00125-013-2893-1
65. Faglia E, Manuela M, Antonella Q, et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J. 2005;149(2):e1-6. doi: 10.1016/j.ahj.2004.07.027
Supplementary files
|
|
1. Рисунок 1. Смертность пациентов в течение 30 суток после острого инфаркта миокарда, по данным экспериментов, завершенных по 1997 год включительно | |
| Subject | ||
| Type | Результаты исследования | |
View
(108KB)
|
Indexing metadata ▾ | |
|
|
2. Рисунок 2. Смертность пациентов по истечению 30 суток после острого инфаркта миокарда, по данным экспериментов, завершенных по 1997 год включительно | |
| Subject | ||
| Type | Результаты исследования | |
View
(128KB)
|
Indexing metadata ▾ | |
|
|
3. Рисунок 3. Смертность пациентов в течение 30 суток после острого инфаркта миокарда, по данным экспериментов, завершенных после 1998 года. | |
| Subject | ||
| Type | Результаты исследования | |
View
(60KB)
|
Indexing metadata ▾ | |
|
|
4. Рисунок 4. Смертность пациентов по истечению 30 суток после острого инфаркта миокарда, по данным экспериментов, завершенных после 1998 года. | |
| Subject | ||
| Type | Результаты исследования | |
View
(59KB)
|
Indexing metadata ▾ | |
Review
For citations:
Kakorin S.V., Iskandaryan R.A., Mkrtumyan A.M. Perspectives on reducing mortality attributed to acute myocardial infarction among patients with type 2 diabetes mellitus in multicenter randomized trials. Diabetes mellitus. 2016;19(2):141-149. (In Russ.) https://doi.org/10.14341/DM200412-6
Views:
1106
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
